Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its upcoming presentations at three investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its upcoming presentations at three investor conferences. These include the Cowen 43rd Annual Health Care Conference on March 7, 2023, the Oppenheimer 33rd Annual Virtual Healthcare Conference on March 15, 2023, and the Stifel 2023 Virtual CNS Days on March 29, 2023. Investors can access a live webcast during the events via the Investors & Media section on the Ionis website, with replays available shortly after. Ionis has been a pioneer in RNA-targeted therapy for over 30 years, focusing on innovative genetic medicine therapies.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was -0.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Cowen 43rd Annual
Health Care Conference onTuesday, March 7, 2023 - Oppenheimer 33rd Annual
Virtual Healthcare Conference onWednesday, March 15, 2023 - Stifel 2023 Virtual CNS Days on
Wednesday, March 29, 2023
A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. The replay will be available on the Ionis website within 48 hours and will be archived for a limited time.
About
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis, visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301757230.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.